Genetic test for assessing hereditary predisposition to cancer
MyCheck Cancer
MyCheck Cancer assesses tumor-associated mutations that are being passed along from generation to generation
Cancer is the world’s second deadliest disease, so it’s unfortunate but no surprise that many families have at least a few members who have had cancer. Sometimes, certain types of cancer seem to run in some families. Although this is often referred to as inherited cancer, what is inherited is the abnormal gene that can lead to cancer, not the cancer itself.
People that inherit these abnormal genes are more susceptible to cancer development. Identifying those at high risk enables implementation of additional screening, surveillance, and interventions.
Indications
People can inherit germline (egg and sperm) mutations in their parents and, with them, the pre-disposition to develop the tumor associated with that alteration.
MyCheck Cancer must be considered by people if there is:
- a clinical history indicative of a hereditary cancer syndrome
- a family history presenting with multiple cancer types
- cancer diagnosed at an unusually young age in the family
- cancer that has developed in both organs of a set of paired organs (e.g., both kidneys, both breasts)
- several close blood relatives that have the same type of cancer
- unusual cases of a specific cancer type (e.g., male breast cancer)
What the test evaluates
MyCheck Cancer is a susceptibility test, that is, it evaluates the predisposition to develop a male hereditary tumor.
The genes analyzed (90 in men, 85 in women) are associated with hereditary forms of the following cancers:
- brain
- thyroid
- liver
- stomach
- kidney
- eyes
- otherwise
- pancreas
- intestine
- bladder
- male and female reproductive system
People with a pathogenic variant in one of these genes have an increased risk of developing certain cancers, many of which may be difficult both to detect and to treat.
Advantages
MyCheck Cancer leverages Next Generation Sequencing (NGS) technology to examine regions of the human genome that tend to get missed by other methods of single or hotspot biomarker testing.
The advantages of this test are:
- It results in risk-reduction and early diagnosis, increasing the chances of successful treatment and survival.
- The early identification of mutations allows the launch of an oncological prevention program based on the monitoring of genetic stability and on lifestyle interventions.
- It determines the genetic causes of hereditary cancers in one’s own family.
How the test is performed
MyCheck Cancer is performed using NGS on the DNA extracted from a peripheral blood sample.
Step 1
The blood sample is sent to Bioscience laboratories for genetic testing
Step 2
DNA is extracted from the blood sample for high-precision genomic analysis
Step 3
A DNA library is prepared and sequenced using NGS technology
Step 4
Advanced bioinformatics ensures rapid data processing and reporting
Request Information About MyCheck Cancer
Contact us today to learn more about the MyCheck Cancer screening test and schedule your appointment.
Contact Us Now
